A new VA-led study highlights the potential of GLP-1 receptor agonists—commonly used for diabetes and weight loss, including semaglutide (Ozempic)—as a novel approach to addressing substance use disorders (SUDs) among veterans. Drawing on data from more than 600,000 Veterans Affairs patients, researchers found that individuals prescribed GLP-1 medications had significantly lower risks of developing addiction across multiple substances, including alcohol, opioids, cannabis, cocaine, and nicotine.
The findings are notable for their breadth: unlike existing pharmacotherapies that target specific substances (e.g., methadone for opioids or varenicline for nicotine), GLP-1 drugs appear to reduce cravings across all major categories of addiction. Researchers suggest this may be due to the drugs’ impact on the brain’s reward system, particularly dopamine signaling, pointing to a shared biological pathway underlying addictive behaviors.
In addition to lowering the risk of developing SUDs (by roughly 14–25% depending on the substance), GLP-1 use among individuals with existing addiction was associated with meaningful reductions in adverse outcomes, including overdoses, hospitalizations, suicidal behavior, and death—with some analyses showing up to a 50% reduction in mortality risk.
Despite these promising findings, researchers emphasize that the study is observational and does not establish causation. The population—primarily older veterans with diabetes—may also limit generalizability. Still, the results underscore a potentially transformative direction for addiction treatment, particularly within veteran populations disproportionately affected by SUDs. Experts call for randomized clinical trials to further evaluate efficacy, safety, and implementation pathways for GLP-1–based interventions in addiction medicine.